Barclays analyst Stephanie Davis maintained a Hold rating on Accolade (ACCD – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $9.19.
Davis covers the Healthcare sector, focusing on stocks such as Laboratory, Quest Diagnostics, and Healthequity. According to TipRanks, Davis has an average return of -6.8% and a 39.93% success rate on recommended stocks.
In addition to Barclays, Accolade also received a Hold from Wells Fargo’s Stan Berenshteyn in a report issued on April 17. However, on April 22, Stifel Nicolaus maintained a Buy rating on Accolade (NASDAQ: ACCD).
Based on Accolade’s latest earnings release for the quarter ending November 30, the company reported a quarterly revenue of $99.37 million and a GAAP net loss of $21.06 million. In comparison, last year the company earned a revenue of $90.95 million and had a GAAP net loss of $39.87 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Accolade (ACCD) Company Description:
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. it generates revenue through providing personalized health guidance solutions to members.
